Mission Therapeutics has divested MTX652, a Phase 2-ready selective USP30 inhibitor for Acute Kidney Injury (AKI), to ASX-listed renal specialist ...

Dimerix Limited (ASX: DXB, "Dimerix") a clinical-stage biopharmaceutical company developing kidney disease treatments, is pleased to announce that it has acquired DMX-652 for all indications from ...

Dimerix has bought an acute kidney injury (AKI) drug from Mission Therapeutics, paying (PDF) $5 million upfront and ...

Acute Kidney Injury Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight DelveInsight's 'Acute Kidney Injury Pipeline ...

Five women in Rajasthan seeking help after alleged postpartum kidney failure have drawn attention to postpartum acute kidney ...

Summer dehydration is more than simple thirst. It means the body's fluid and electrolyte balance has broken down, and it can ...

The search for a better biomarker than creatine for acute kidney injury (AKI) has been “long and elusive.” However, could researchers be on the right path now? “The thinking is moving away from trying ...

Understanding and categorizing the various types of tubulointerstitial responses in acute kidney injury (AKI) may lead to the development of new treatments for the condition, according to Yale School ...

UK biotech company Mission Therapeutics has agreed to hand its acute kidney injury candidate MTX652 to Australian renal ...

Patients who take a calcium-channel blocker for high blood pressure and then receive a prescription for clarithromycin, one ...

Serious damage to short-term kidney function—known as acute kidney injury, or AKI—can be fatal and also increase the risk of irreversible chronic kidney disease. It can be triggered by stressors ...

Five women from Rajasthan's Kota suffering from postpartum kidney failure have refused to continue dialysis and intensified ...